-
Je něco špatně v tomto záznamu ?
Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patients
M. Solar, E. Malirova, M. Ballon, R. Pelouch, J. Ceral,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem
NLK
Open Access Digital Library
od 1948-06-01
Open Access Digital Library
od 1997-07-01
PubMed
22253400
DOI
10.1530/eje-11-0914
Knihovny.cz E-zdroje
- MeSH
- aldosteron krev MeSH
- algoritmy MeSH
- antagonisté mineralokortikoidních receptorů aplikace a dávkování terapeutické užití MeSH
- antihypertenziva aplikace a dávkování terapeutické užití MeSH
- diagnostické techniky endokrinologické MeSH
- diuretika aplikace a dávkování terapeutické užití MeSH
- dospělí MeSH
- hyperaldosteronismus diagnóza farmakoterapie epidemiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- náhrada léků využití MeSH
- odhad potřeb statistika a číselné údaje MeSH
- renin-angiotensin systém účinky léků fyziologie MeSH
- senioři MeSH
- validační studie jako téma MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
OBJECTIVE: Confirmatory testing of suspected primary aldosteronism (PA) requires an extensive medication switch that can be difficult for patients with severe complicated hypertension and/or refractory hypokalemia. For this reason, we investigated the effect of chronic antihypertensive medication on confirmatory testing results. To allow the results to be interpreted, the reproducibility of confirmatory testing was also evaluated. DESIGN AND METHODS: The study enrolled 114 individuals with suspected PA who underwent two confirmatory tests. The patients were divided into two groups. In Group A, both tests were performed on the guidelines-recommended therapy, i.e. not interfering with the renin-angiotensin-aldosterone system. In Group B, the first test was performed on chronic therapy with the exclusion of thiazides, loop diuretics, and aldosterone antagonists; and the second test was performed on guidelines-recommended therapy. Saline infusion, preceded by oral sodium loading, was used to suppress aldosterone secretion. RESULTS: Agreement in the interpretation of the two confirmatory tests was observed in 84 and 66% of patients in Groups A and B respectively. For all 20 individuals in Group A who ever had end-test serum aldosterone levels ≥240 pmol/l, aldosterone was concordantly nonsuppressible during the other test. Similarly, for all 16 individuals in Group B who had end-test serum aldosterone levels ≥240 pmol/l on modified chronic therapy, aldosterone remained nonsuppressible with guidelines-recommended therapy. CONCLUSION: Confirmatory testing performed while the patient is on chronic therapy without diuretics and aldosterone antagonists can confirm the diagnosis of PA, provided serum aldosterone remains markedly elevated at the end of saline infusion.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12024109
- 003
- CZ-PrNML
- 005
- 20121207100901.0
- 007
- ta
- 008
- 120815e20120117enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1530/eje-11-0914 $2 doi
- 035 __
- $a (PubMed)22253400
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Solar, Miroslav $u Departments of Internal Medicine Nuclear Medicine, Charles University Prague, University Hospital Hradec Kralove, Sokolska 581, Hradec Kralove, Czech Republic.
- 245 10
- $a Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patients / $c M. Solar, E. Malirova, M. Ballon, R. Pelouch, J. Ceral,
- 520 9_
- $a OBJECTIVE: Confirmatory testing of suspected primary aldosteronism (PA) requires an extensive medication switch that can be difficult for patients with severe complicated hypertension and/or refractory hypokalemia. For this reason, we investigated the effect of chronic antihypertensive medication on confirmatory testing results. To allow the results to be interpreted, the reproducibility of confirmatory testing was also evaluated. DESIGN AND METHODS: The study enrolled 114 individuals with suspected PA who underwent two confirmatory tests. The patients were divided into two groups. In Group A, both tests were performed on the guidelines-recommended therapy, i.e. not interfering with the renin-angiotensin-aldosterone system. In Group B, the first test was performed on chronic therapy with the exclusion of thiazides, loop diuretics, and aldosterone antagonists; and the second test was performed on guidelines-recommended therapy. Saline infusion, preceded by oral sodium loading, was used to suppress aldosterone secretion. RESULTS: Agreement in the interpretation of the two confirmatory tests was observed in 84 and 66% of patients in Groups A and B respectively. For all 20 individuals in Group A who ever had end-test serum aldosterone levels ≥240 pmol/l, aldosterone was concordantly nonsuppressible during the other test. Similarly, for all 16 individuals in Group B who had end-test serum aldosterone levels ≥240 pmol/l on modified chronic therapy, aldosterone remained nonsuppressible with guidelines-recommended therapy. CONCLUSION: Confirmatory testing performed while the patient is on chronic therapy without diuretics and aldosterone antagonists can confirm the diagnosis of PA, provided serum aldosterone remains markedly elevated at the end of saline infusion.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a aldosteron $x krev $7 D000450
- 650 _2
- $a antagonisté mineralokortikoidních receptorů $x aplikace a dávkování $x terapeutické užití $7 D000451
- 650 _2
- $a algoritmy $7 D000465
- 650 _2
- $a antihypertenziva $x aplikace a dávkování $x terapeutické užití $7 D000959
- 650 _2
- $a diagnostické techniky endokrinologické $7 D003940
- 650 _2
- $a diuretika $x aplikace a dávkování $x terapeutické užití $7 D004232
- 650 _2
- $a náhrada léků $x využití $7 D057915
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperaldosteronismus $x diagnóza $x farmakoterapie $x epidemiologie $7 D006929
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a odhad potřeb $x statistika a číselné údaje $7 D020380
- 650 _2
- $a renin-angiotensin systém $x účinky léků $x fyziologie $7 D012084
- 650 _2
- $a validační studie jako téma $7 D054928
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Malirova, Eva
- 700 1_
- $a Ballon, Marek
- 700 1_
- $a Pelouch, Radek
- 700 1_
- $a Ceral, Jiri
- 773 0_
- $w MED00009634 $t European journal of endocrinology / European Federation of Endocrine Societies $x 1479-683X $g Roč. 166, č. 4 (20120117), s. 679-86
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22253400 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120815 $b ABA008
- 991 __
- $a 20121207100935 $b ABA008
- 999 __
- $a ok $b bmc $g 946257 $s 781437
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 166 $c 4 $d 679-86 $e 20120117 $i 1479-683X $m European journal of endocrinology $n Eur J Endocrinol $x MED00009634
- LZP __
- $a Pubmed-20120815/12/02